Tissue microarray (TMA) versus whole section immunohistochemistry in the assessment of ER/PR and Her-2/neu status in a breast cancer series from Sudan.

Tissue microarray (TMA) versus whole section immunohistochemistry in the assessment of ER/PR and Her-2/neu status in a breast cancer series from Sudan.